WYZGA MICHAEL S 4
4 · Tvardi Therapeutics, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Tvardi (TVRD) Director Michael Wyzga Receives 6,000-Share Award
What Happened
Michael S. Wyzga, a director of Tvardi Therapeutics, was granted a derivative award covering 6,000 shares on June 9, 2026. The filing shows an acquisition at $0.00 (no cash paid at grant). This is an award/compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-09; reported on Form 4 filed 2026-06-11 (timely filing).
- Type: Grant / award of a derivative instrument covering 6,000 shares (transaction code A). Reported acquisition price: $0.00.
- Shares owned after transaction: Not specified in the Form 4 filing.
- Vesting: Per the filing footnote, 100% of the shares underlying the award vest on the earlier of June 9, 2027 or the issuer’s next annual meeting of stockholders, subject to continuous service.
- No immediate sale or cash exercise reported.
Context: This appears to be a standard director compensation award (option/RSU-style derivative) with a one-year or event-based vesting condition. Such grants are common and do not by themselves signal an insider buying or selling stock; they represent future potential ownership contingent on continued service and vesting.
Insider Transaction Report
Form 4
WYZGA MICHAEL S
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-06-09+6,000→ 6,000 totalExercise: $2.78Exp: 2036-06-08→ Common Stock (6,000 underlying)
Footnotes (1)
- [F1]100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Signature
/s/ Dan Conn, Attorney-in-Fact|2026-06-11